AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
暂无分享,去创建一个
Andrew P Thomas | C. Rooney | E. Kilgour | T. Klinowska | M. Mellor | L. Mooney | D. Baker | T. Coleman | P. Gavine | Sarah Beck | A. Brooks | Katherine Al-Kadhimi
[1] M. Moran,et al. A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. , 2011, Blood.
[2] M. Maitland,et al. Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment , 2009, Clinical Cancer Research.
[3] A. Ullrich,et al. Resistance to Chemotherapy Is Associated with Fibroblast Growth Factor Receptor 4 Up-Regulation , 2009, Clinical Cancer Research.
[4] P. Pollock,et al. Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma , 2008, Clinical Cancer Research.
[5] Matthew A Powell,et al. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. , 2008, Cancer research.
[6] Robert A. Weinberg,et al. Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.
[7] W. Sommergruber,et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. , 2008, Cancer research.
[8] S. Wedge,et al. Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy , 2008, Clinical Cancer Research.
[9] Q. Rao,et al. [Promoter methylation status of PTEN gene and the effect of induced demethylation in leukemia cell lines]. , 2008, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.
[10] Cem Elbi,et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. , 2008, Cancer research.
[11] P. Pollock,et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes , 2007, Oncogene.
[12] C. Robson,et al. Selective over‐expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer , 2007, The Journal of pathology.
[13] Paul D. Martin,et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models , 2007, Molecular Cancer Therapeutics.
[14] J. Nardone,et al. Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. , 2006, Blood.
[15] N. Sebire,et al. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. , 2006, The EMBO journal.
[16] Neil J. Sebire,et al. FGF‐2 protects small cell lung cancer cells from apoptosis through a complex involving PKCε, B‐Raf and S6K2 , 2006 .
[17] J. Keats,et al. Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma , 2006, Leukemia & lymphoma.
[18] Adel H Jebar,et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma , 2005, Oncogene.
[19] S. Barry,et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. , 2005, Cancer research.
[20] Y. Yen,et al. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma , 2005, Molecular Cancer Therapeutics.
[21] Y. Yen,et al. Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor. , 2005, Oligonucleotides.
[22] Hong Chang,et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. , 2004, Blood.
[23] S. Ethier,et al. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. , 2004, Molecular cancer research : MCR.
[24] P. L. Bergsagel,et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. , 2004, Blood.
[25] Donna Albertson,et al. Genomic and Expression Analysis of the 8p11–12 Amplicon in Human Breast Cancer Cell Lines , 2004, Cancer Research.
[26] J. Melo,et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. , 2001, Blood.
[27] D. Fabbro,et al. Su-6668. SUGEN. , 2001, Current opinion in investigational drugs.
[28] A. Adjei,et al. Blocking oncogenic Ras signaling for cancer therapy. , 2001, Journal of the National Cancer Institute.
[29] I. Lax,et al. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[30] J. G. Park,et al. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. , 2001, Cancer research.
[31] W. Kuehl,et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. , 2001, Blood.
[32] J. Au,et al. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[33] Joseph Schlessinger,et al. Crystal Structures of Two FGF-FGFR Complexes Reveal the Determinants of Ligand-Receptor Specificity , 2000, Cell.
[34] P. L. Bergsagel,et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. , 2000, Blood.
[35] P. Klint,et al. Signal transduction by fibroblast growth factor receptors. , 1999, Frontiers in bioscience : a journal and virtual library.
[36] D. Birnbaum,et al. The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. , 1999, Blood.
[37] R. Aguiar,et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. , 1998, Blood.
[38] H. Yoshiji,et al. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. , 1997, Cancer research.
[39] E. Schröck,et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.
[40] C. Basilico,et al. Activation of FGF receptors by mutations in the transmembrane domain , 1997, Oncogene.
[41] D. Ornitz,et al. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia , 1996, Nature Genetics.
[42] Tracy T Batchelor,et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.
[43] D. Chopin,et al. Short Communication Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors , 2001 .
[44] A. Rehemtulla,et al. Statement of findings , 1999 .